
Axsome's AXS-05 Significantly Reduced Risk of Relapse in Alzheimer Agitation in Phase 3 ACCORD Trial
Findings from phase 3 ACCORD clinical trial demonstrated rapid and sustained clinical response in patients with Alzheimer disease agitation with no new safety signals reported.












